Denali Therapeutics Inc. (DNLI) Misses Q4 EPS by 6c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.86), $0.06 worse than the analyst estimate of ($0.80).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks
• Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral